SCHEMBL13495362

SCHEMBL13495362

CON1C(=O)c2cccc3cc(O)cc(c23)C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD1 O95696 1/20 0.52
TAF1 P21675 1/20 0.52
BRPF1 P55201 1/20 0.52
TDP1 Q9NUW8 2/20 0.46
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 4/20 0.45
MEN1 O00255 3/20 0.45
HSD17B10 Q99714 2/20 0.45
ERCC1 P07992 1/20 0.45
FEN1 P39748 1/20 0.45
ERCC4 Q92889 1/20 0.45
MPO P05164 1/20 0.44
CYP1B1 Q16678 2/20 0.43
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13495341 0.84 ALDH1A1 (0.50) TDP1KMT2AKDM4EALDH1A1HPGD
SCHEMBL10040988 0.84 TDP1 (0.60) TDP1KMT2AKDM4EALDH1A1HPGD
SCHEMBL13495351 0.83 TDP1 (0.47) TDP1KMT2AKDM4EALDH1A1HPGD
SCHEMBL8927321 0.83 BRD1 (0.59) BRD1TAF1BRPF1TDP1KMT2A
SCHEMBL13495348 0.82 RAD52 (0.60) TDP1KMT2AKDM4EALDH1A1HPGD
SCHEMBL13496099 0.81 TDP1 (0.46) TDP1KMT2AKDM4EALDH1A1HPGD
SCHEMBL7706718 0.81 ERCC1 (0.70) BRD1TAF1BRPF1TDP1KMT2A
SCHEMBL10703784 0.80 BRD1 (0.52) BRD1TAF1BRPF1TDP1KMT2A
SCHEMBL13885576 0.79 RXFP1 (0.52) BRD1TAF1BRPF1KMT2AALDH1A1
SCHEMBL7703791 0.79 MAPT (0.49) BRD1TAF1BRPF1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC BRD1 151/4885TAF1 841/4885BRPF1 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.